Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Market: Pharmaceuticals and Healthcare

Global, 111 pages report, published by GlobalData

Report ThumbnailAugust-2011
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Asthma Therapeutics market. The report identifies the key trends shaping and driving the global Asthma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Asthma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Asthma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Asthma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Asthma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Asthma Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Asthma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Asthma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Asthma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Asthma Therapeutics market landscape? – Identify, understand and capitalize.
  • 1.2 List of Figures
  • Figure 1: Asthma Prevalence Control Extrapolated to The European Union Population (in millions) 8
  • Figure 2: Asthma Etiology Hypothesis With Common Triggers 10
  • Figure 3: Classification of Asthma Control 11
  • Figure 4: T lymphocytes in Allergic Asthma 12
  • Figure 5: Phases of Asthmatic Attack. 13
  • Figure 6: Treatment Of Chronic asthma 15
  • Figure 7: Asthma Referral Pathway 16
  • Figure 8: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18
  • Figure 9: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19
  • Figure 10: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20
  • Figure 11: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21
  • Figure 12: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22
  • Figure 13: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23
  • Figure 14: Asthma Therapeutics Market, Germany, Revenue ($m), 2005–2010 24
  • Figure 15: Asthma Therapeutics Market, Germany, Forecast ($m), 2010–2018 25
  • Figure 16: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26
  • Figure 17: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27
  • Figure 18: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28
  • Figure 19: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29
  • Figure 20: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30
  • Figure 21: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31
  • Figure 22: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32
  • Figure 23: Asthma Therapeutics Market, Japan, Forecast ($m), 2010–2018 33
  • Figure 24: Opportunity and Unmet Need in the Asthma Therapeutics Market, 2010 35
  • Figure 25: Asthma Therapeutics, Strategic Competitor Assessment, 2010 36
  • Figure 26: Asthma Therapeutics, Molecular Structure of Zenhale 52
  • Figure 27: Asthma Therapeutics – Pipeline by Phase of Development, 2011 56
  • Figure 28: Asthma Therapeutics, Technology Trends Analytics Framework, 2011 63
  • Figure 29: Asthma Therapeutics, Technology Trends Analytics Framework, Description, 2011 64
  • Figure 30: Asthma Therapeutics, Pipeline by Mechanism of Action (%), 2011 65
  • Figure 31: Asthma Therapeutics, Molecular Structure of Relovair 67
  • Figure 32: Asthma Therapeutics, Molecular Structure of Foster 68
  • Figure 33: Structure of Andolast 71
  • Figure 34: KCA 757/MN001 Structure 72
  • Figure 35: Asthma Therapeutics, Clinical Trials by Country, 2011 74
  • Figure 36: Asthma Therapeutics, Clinical Trials by Phase (%), 2011 75
  • Figure 37: Asthma Therapeutics, Clinical Trials by Status (%), 2011 76
  • Figure 38: Asthma Therapeutics, Overall Sponsors (%), 2011 77
  • Figure 39: Asthma Therapeutics, Prominent Sponsors (%), 2011 78
  • Figure 40: Asthma Therapeutics, Top Companies Participating in Clinical Trials, 2011 79
  • Figure 41: Asthma Therapeutics Market, Drivers and Restraints, 2011 80
  • Figure 42: Implications for Future Market Competition in the Asthma Market, 2011 81
  • Figure 43: Asthma Therapeutics Market, Pipeline by Company, 2011 82
  • Figure 44: GlobalData Market Forecasting Model 109
  • 1.1 List of Tables
  • Table 1: Asthma Therapeutics Market, Global, Revenue ($bn), 2005–2010 18
  • Table 2: Asthma Therapeutics Market, Global, Forecast ($bn), 2010–2018 19
  • Table 3: Asthma Therapeutics Market, The US, Revenue ($bn), 2005–2010 20
  • Table 4: Asthma Therapeutics Market, The US, Forecast ($bn), 2010–2018 21
  • Table 5: Asthma Therapeutics Market, France, Revenue ($m), 2005–2010 22
  • Table 6: Asthma Therapeutics Market, France, Forecast ($m), 2010–2018 23
  • Table 7: Asthma Therapeutics Market, Germany, Forecast ($m), 2005–2010 24
  • Table 8: Asthma Therapeutics Market, Germany, Forecasts ($m), 2010–2018 25
  • Table 9: Asthma Therapeutics Market, Italy, Revenue ($m), 2005–2010 26
  • Table 10: Asthma Therapeutics Market, Italy, Forecast ($m), 2010–2018 27
  • Table 11: Asthma Therapeutics Market, Spain, Revenue ($m), 2005–2010 28
  • Table 12: Asthma Therapeutics Market, Spain, Forecast ($m), 2010–2018 29
  • Table 13: Asthma Therapeutics Market, The UK, Revenue ($m), 2005–2010 30
  • Table 14: Asthma Therapeutics Market, The UK, Forecast ($m), 2010–2018 31
  • Table 15: Asthma Therapeutics Market, Japan, Revenue ($m), 2005–2010 32
  • Table 16: Asthma Therapeutics Market, Japan, Forecast ($bn), 2010–2018 33
  • Table 17: Adverse Reactions With ≥3% Incidence With Advair Diskus in Adult and Adolescent Patients With Asthma. 38
  • Table 18: Pooled Data From Three 12-Week, Double-Blind, Placebo-Controlled Clinical Asthma Trials In Patients 12 Years And Older 40
  • Table 19: Adverse Experiences Occurring in ≥1% of Patients with an Incidence Greater than that in Patients Treated with Placebo 42
  • Table 20: Effect of Singulair on Primary and Secondary Endpoints in a Multinational Placebo-Controlled Trial 43
  • Table 21: Number And Frequency Of Adverse Experiences In Patients From Multiple-Dose Controlled Clinical Trials 44
  • Table 22: Efficacy Results of Study 40 of Foradil 45
  • Table 23: Symptom and Rescue Medication Use (Adults with Asthma) 45
  • Table 24: A Comparison of Adverse Events Reported by ≥1% of Zafirlukast-Treated Patients 47
  • Table 25: Mean Change from Baseline at Study End Point 47
  • Table 26: Adverse Reaction Incidence in Two 12-Week Clinical Trials in Adult and Adolescent Patients With Asthma 50
  • Table 27: Study Design of Phase III trial 53
  • Table 28: Clinical Trial with Dulera 100 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction In Lung Function 53
  • Table 29: Clinical Trial With Dulera 200 mcg/5 mcg Clinically Judged Deterioration in Asthma or Reduction in Lung Function 54
  • Table 30: Asthma Therapeutics, NDA Filed Products, 2011 56
  • Table 31: Asthma Therapeutics, Phase III Pipeline, 2011 57
  • Table 32: Asthma Therapeutics, Phase II Pipeline, 2011 58
  • Table 33: Asthma Therapeutics, Phase I Pipeline, 2011 60
  • Table 34: Asthma Therapeutics, Pre-Clinical Pipeline, 2011 61
  • Table 35: Asthma Therapeutics, Discovery Pipeline, 2011 62
  • Table 36: Asthma Therapeutics – Most Promising Drugs Under Clinical Development, 2011 66
  • Table 37:Study Details of CHF 1535 100/6 NEXT DPI 69
  • Table 38: Asthma Therapeutics, Clinical Trials by Country, 2011 74
  • Table 39: Asthma Therapeutics – Clinical Trials by Phase, 2011 75
  • Table 40: Asthma Therapeutics, Clinical Trials by Status , 2011 76
  • Table 41: Asthma Therapeutics, Prominent Sponsors, 2011 78
  • Table 42: Asthma Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 79
  • Table 43: GSK – Respiratory and Immuno-inflamation Pipeline Products, 2011 85
  • Table 44: GSK –Asthma Pipeline Products, 2011 85
  • Table 45: Merck & Co., Inc. – Respiratory Pipeline, 2011 87
  • Table 46: Merck & Co., Inc. – Asthma pipeline, 2011 88
  • Table 47: Novartis AG – Respiratory pipeline 89
  • Table 48: Novartis AG – Asthma Pipeline 89
  • Table 49: AstraZeneca – Respiratory Pipeline Products, 2011 91
  • Table 50: AstraZeneca – Asthma Pipeline Products, 2011 91
  • Table 51: Orion Corporation – Respiratory Pipeline, 2011 96
  • Table 52: Orion Corporation – Respiratory Pipeline, 2011 97
  • Table 53: Asthma Therapeutics, Global, Deals, 2009-2011 100
  • 1 Table of Contents
  • 1 Table of Contents 3
  • 1.1 List of Tables 5
  • 1.2 List of Figures 6
  • 2 Asthma Therapeutics: Introduction 7
  • 2.1 Disease Overview 7
  • 2.1.1 Epidemiology 7
  • 2.1.2 Classic Signs and Symptoms 9
  • 2.1.3 Etiology 9
  • 2.1.4 Diagnosis 10
  • 2.1.5 Classification 11
  • 2.1.6 Pathogenesis of Asthma 12
  • 2.1.7 Treatment 14
  • 2.1.8 Referral Pathway 16
  • 2.2 GlobalData Pipeline Report Guidance 17
  • 3 Asthma Therapeutics: Market Characterization 18
  • 3.1 Asthma Therapeutics Market Size (2005–2010) – Global 18
  • 3.2 Asthma Therapeutics Market Forecast (2010–2018) – Global 19
  • 3.3 Asthma Therapeutics Market Size (2005–2010) – The US 20
  • 3.4 Asthma Therapeutics Market Forecast (2010–2018) – The US 21
  • Asthma Therapeutics Market Size (2005–2010) – France 22
  • 3.5 Asthma Therapeutics Market Forecast (2010–2018) – France 23
  • 3.6 Asthma Therapeutics Market Size (2005–2010) – Germany 24
  • 3.7 Asthma Therapeutics Market Forecast (2010–2018) – Germany 25
  • 3.8 Asthma Therapeutics Market Size (2005–2010) – Italy 26
  • 3.9 Asthma Therapeutics Market Forecast (2010–2018) – Italy 27
  • 3.10 Asthma Therapeutics Market Size (2005–2010) – Spain 28
  • 3.11 Asthma Therapeutics Market Forecast (2010–2018) – Spain 29
  • 3.12 Asthma Therapeutics Market Size (2005–2010) – The UK 30
  • 3.13 Asthma Therapeutics Market Forecast (2010–2018) – The UK 31
  • 3.14 Asthma Therapeutics Market Size (2005–2010) – Japan 32
  • 3.15 Asthma Therapeutics Market Forecast (2010–2018) – Japan 33
  • 3.16 Drivers and Barriers for the Asthma Therapeutics Market 34
  • 3.16.1 Drivers for the Asthma Therapeutics Market 34
  • 3.16.2 Barriers for the Asthma Therapeutics Market 34
  • 3.17 Opportunity and Unmet Need Analysis 35
  • 3.18 Key Take away 35
  • 4 Asthma Therapeutics: Competitive Assessment 36
  • 4.1 Overview 36
  • 4.2 Strategic Competitor Assessment 36
  • 4.3 Marketed Product Profiles 37
  • 4.3.1 Advair Diskus (fluticasone propionate and salmeterol inhalation powder) 37
  • 4.3.2 Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol) 40
  • 4.3.3 Singulair (montekeulast sodium) 41
  • 4.3.4 Foradil (formoterol fumarate inhalation powder) 43
  • 4.3.5 Accolate (zafirlukast) 46
  • 4.3.6 Xolair (omalizumab) 48
  • 4.3.7 Serevent Diskus (salmaterol xinafoate inhalation powder) 49
  • 4.3.8 Dulera/Zenhale (SCH 418131) 51
  • 5 Asthma Therapeutics: Pipeline Assessment 55
  • 5.1 Overview 55
  • 5.2 Strategic Pipeline Assessment 55
  • 5.3 Asthma Therapeutics Pipeline – Pipeline by Phases of Development 56
  • 5.3.1 Asthma Therapeutics – NDA Filed Products 56
  • 5.3.2 Asthma Therapeutics – Phase III Pipeline 57
  • 5.3.3 Asthma Therapeutics – Phase II Pipeline 58
  • 5.3.4 Asthma Therapeutics – Phase I Pipeline 60
  • 5.3.5 Asthma Therapeutics – Pre-Clinical Pipeline 61
  • 5.3.6 Asthma Therapeutics – Discovery Pipeline 62
  • 5.3.7 Technology Trends Analytic Framework 63
  • 5.4 Asthma Therapeutics –Pipeline by Mechanism of Action 65
  • 5.5 Asthma Therapeutics – Promising Drugs under Clinical Development 66
  • 5.6 Molecule Profile for Promising Drugs under Clinical Development 67
  • 5.6.1 Relovair 67
  • 5.6.2 CHF 1535 100/6 NEXT DPI or CHF 1535 pMDI 68
  • 5.6.3 Flutiform (fluticasone proprionate and formoterol fumarate inhalation aerosol) 69
  • 5.6.4 Reslizumab 69
  • 5.6.5 VR315 70
  • 5.6.6 Andolast (CR 2039): 71
  • 5.6.7 KCA-757/MN-001 71
  • 5.6.8 Budesonide-Formoterol Formulation 72
  • 5.6.9 Fluticasone-Salmeterol Formulation 73
  • 5.7 Key Takeaway 73
  • 6 Asthma Therapeutics: Clinical Trials Mapping 74
  • 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 74
  • 6.2 Clinical Trials by Phase 75
  • 6.3 Clinical Trials by Trial Status 76
  • 6.4 Prominent Sponsors 77
  • 6.5 Top Companies Participating in Asthma Therapeutics Clinical Trials 79
  • 7 Strategic Assessment 80
  • 7.1 Key Events Impacting the Future Market 80
  • 7.2 Asthma Therapeutics: Implications for Future Market Competition 81
  • 8 Asthma Therapeutics: Future Players 82
  • 8.1 Introduction 82
  • 8.2 Company Profiles 83
  • 8.2.1 GlaxoSmithKline Plc. 83
  • 8.2.2 Merck & Co., Inc. 86
  • 8.2.3 Novartis AG 88
  • 8.2.4 AstraZeneca 90
  • 8.2.5 Cephalon, Inc. 92
  • 8.2.6 Vectura 94
  • 8.2.7 Orion Corporation 95
  • 8.2.8 Rottapharma SPA 97
  • 8.2.9 SkyePharma PLC 98
  • 9 Asthma Therapeutics: Licensing and Partnership Deals 100
  • 10 Asthma Therapeutics: Appendix 105
  • 10.1 Market Definitions 105
  • 10.2 Abbreviations 105
  • 10.3 Methodology 106
  • 10.3.1 Coverage 106
  • 10.3.2 Secondary Research 107
  • 10.3.3 Forecasting 107
  • 10.3.4 Primary Research 109
  • 10.3.5 Expert Panel Validation 110
  • 10.4 Contact Us 110
  • 10.5 Disclaimer 110
  • 10.6 Bibliography 110

Please select a license type

Share

Related Products

GlobalDataAsthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018Product ThumbnailAsthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018, Industry ReportProduct #: 64827
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved